CLINICAL TRIALS PROFILE FOR CASIMERSEN
✉ Email this page to a colleague
All Clinical Trials for CASIMERSEN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02500381 ↗ | Study of SRP-4045 and SRP-4053 in Participants With Duchenne Muscular Dystrophy (DMD) | Recruiting | Sarepta Therapeutics | Phase 3 | 2016-09-28 | The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053 compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively. |
| NCT02500381 ↗ | Study of SRP-4045 and SRP-4053 in Participants With Duchenne Muscular Dystrophy (DMD) | Recruiting | Sarepta Therapeutics, Inc. | Phase 3 | 2016-09-28 | The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053 compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively. |
| NCT03532542 ↗ | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | Enrolling by invitation | Sarepta Therapeutics | Phase 3 | 2018-08-02 | The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD). |
| NCT03532542 ↗ | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | Enrolling by invitation | Sarepta Therapeutics, Inc. | Phase 3 | 2018-08-02 | The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD). |
| NCT04179409 ↗ | A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD Duplications | Active, not recruiting | Sarepta Therapeutics, Inc. | Phase 2 | 2020-02-18 | This is an 48-week open-label study to determine the efficacy and safety of casimersen, eteplirsen, or golodirsen for the treatment of boys with duchenne muscular dystrophy who have a single exon duplication of either exon 45, 51 or 53, respectively. There will be weekly infusions and two muscle biopsies at baseline and at month 12. |
| NCT04179409 ↗ | A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD Duplications | Active, not recruiting | Kevin Flanigan | Phase 2 | 2020-02-18 | This is an 48-week open-label study to determine the efficacy and safety of casimersen, eteplirsen, or golodirsen for the treatment of boys with duchenne muscular dystrophy who have a single exon duplication of either exon 45, 51 or 53, respectively. There will be weekly infusions and two muscle biopsies at baseline and at month 12. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CASIMERSEN
Condition Name
Clinical Trial Locations for CASIMERSEN
Trials by Country
Clinical Trial Progress for CASIMERSEN
Clinical Trial Phase
Clinical Trial Sponsors for CASIMERSEN
Sponsor Name
